Presentations

Presentations

BARDA INDUSTRY DAY 2020
October 27th, 2020 | VIRTUAL EVENT
PRESENTATION
& TIMING
PRESENTERS
MORNING & PROGRAM OVERVIEW SESSIONS
00:04:20 – 00:19:00 Watch: ASPR WELCOME! – Dr. Robert Kadlec, M.D., MTM&H, M.S.: Assistant Secretary for Preparedness and Response
00:19:00 – 00:37:15 Watch: HIGHLIGHTED GOVERNMENT PARTNER – Mr. Douglas Bryce, Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)
00:37:15 – 00:50:36 Watch: INDUSTRY PARTNER –Evan Loh, M.D.: Chief Executive Office Paratek Pharmaceuticals
00:50:36 – 00:58:07 Watch: HIGHLIGHTED SPEAKER – Mr. Adam Boehler, MBA: Chief Executive Officer of the new U.S. International Development Finance Corporation (DFC)
00:58:07 – 01:11:38 Watch: HIGHLIGHTED SPEAKER – Michelle McMurry-Heath, M.D., PH.D: President and Chief Executive Office of Biotechnology Innovation Organization (BIO)
01:11:38 – 01:26:25 Watch: BARDA DIRECTOR’S UPDATE – Dr. Gary Disbrow: Acting Director, Biomedical Advanced Research and Development Authority (BARDA)
01:26:25 – 01:35:59 Division of Influenza and Emerging Infectious Diseases (IEID)
Dr. Robert Johnson, Director
01:35:35 – 01:40:38 Division of Detection, Diagnostics, & Devices Infrastructure (DDDI)
Mr. Rodney Wallace, Director
01:40:38 – 01:49:00 Division of Research, Innovation, and Ventures (DRIVe)
Dr. Sandeep Patel, Director
01:49:00 – 01:57:22 Division of Contract Management & Acquisitions (CMA)
Mr. Enrique Mañán, Acting Direorctor
01:57:22 – 02:08:29 Division of Chemical, Biological, Radiological and Nuclear Medical Countermeasures (CBRN)
Dr. Christopher Houchens, Director
02:10:46 - 02:19:36 pm Quickfire Challenge Winner
02:19:36 - 02:19:36 pm BARDA #MakingCountermeasures
VIDEO
PRESENTATION
BREAKOUT SESSIONS
Session 1 Track 1: CBRN Vaccine Programs: Vaccines - Lindsay Parish, PhD; Antivirals & Antitoxins - David Boucher, PhD; Antibacterials - Brian Tse, PhD.
Session 1 Track 2: Division of Clinical Development Overview - Robert Walker; Clinical Operations Branch - Elizabeth Formentini; Biostatistics Branch - James Zhou; Clinical Operations Branch - Marcy Beth Grace
Session 1 Track 3: Blue Knight Panel - Sparking Innovation to Improve the Nation's Response to 21st Century Health Security Threats: Moderator - Ashley Cecere
Session 1 Track 4: Pharmaceutical Countermeasure Infrastructure: Collaborating with our Manufacturing Partners - Arlene Joyner; The National Biopharmaceutical Manufacturing Partnership (BioMaP) - Tim Belski
Session 2 Track 1: Division of Nonclinical Development Overview - April Brys & Claiborne Hughes & James Little; SARS-CoV-2 Response Planning - James Little; SARS-CoV-2 Model Development and Utilization - Allison Totura; SARS-CoV-2 Assay Development - Ashley Smith; BARDA Nonclinical DevelopmentLooking Forward - Claiborne Hughes
Session 2 Track 2: Thermal Burn Medical Countermeasure Program - Janelle Hurwitz; Reimagining Community Preparedness for Mass Casualty Chemical Incidents - William Coley; Radiological & Nuclear Countermeasures Program - John Esker
Session 2 Track 3: Investing in the Future of Health Security Division of Research Innovation & Ventures (DRIVe) - Sandeep Patel
Session 2 Track 4: Contract Management & Acquisitions: Medicalcountermeasures Support Services (MCM-S) - Jeff Schmidt; DRIVe Acquisitions Team - Matt Clay; Station Support & Administrative Contracting (SSAC) - Roseary Hill; Medical Countermeasures Development (MCM-D) - James Harris
Session 3 Track 1: Influenza and Emerging Infectious Diseases: Vaccines - Armen Donabedian; Therapeutics - Kimberly Armstrong; Pandemic Influenza Vaccine Stockpile - Jonathan Seals;
Session 3 Track 2: Regulatory & Quality Affairs - Nina El-Badry; Emergency Use Authorizations (EUAs) - Susan Hollingsworth; JPEO-CBRND - COL Ryan Eckmeier
Session 3 Track 3: CARB-X and Drive Accelerator Networks Wrap Around Services to Prepare for Competitive Funding Engagements - Cameron Bess and Justin Yang
Session 3 Track 4: Detection, Diagnostics, & Devices Infrastructure (DDDI) Division - Rodney Wallace; COVID-19 Timeline & Contracting Approach - John Lee; COVID-19 Dx Manufacturing Capacity Expansion - Charles Daitch; Diagnostics & Medical Devices (The Other Countermeasures); Keys to a Successful White Paper - Paul Eder; EZ-BAA & BAA Solicitation Updates - Jordan Smith
LIGHTNING TALKS - SESSION 1: VACCINES/THERAPEUTICS
00:00:00 – 00:06:27 Watch: Adaptive Biotechnologies - Understanding Immunity to SARS-CoV-2: The T Cell Side of the Equation
00:06:28 - 00:10:07 Watch: Instanosis Inc. - Ultransensitive SARS-CoV-2 Antigen Detection Using Microbubbling
00:10:08 – 00:15:42 Watch: MeMed - MeMed BV™/Key™: Responding Today, Preparing for Tomorrow. A Host-Protein Test for Combatting Antimicrobial Resistance Plus Biomarkers to Aid in Outbreak Management
00:15:43 – 00:21:13 Watch: The University of Kansas - Development of a Handheld Radiation Bio-Dosimeter for Point-of-Care Use
00:21:14 – 00:26:32 Watch: PhenoMx - Multi-Parametric Quantitative Whole-Body Assessment of COVID-19 Infected Individuals for Risk of Chronic Long-Term Conditions
00:26:33 – 00:31:36 Watch: Promethean LifeSciences - GammaGraft for Burn and Wound Medical Countermeasures Stockpiling
00:31:37 – 00:35:58 Watch: PharmaJet - Needle-free Delivery of Pandemic Vaccines
00:35:59 – 00:41:38 Watch: Vir Biotechnology, Inc - Immunological Tools for Pandemic Preparedness
00:41:39 – 00:47:37 Watch: Autonomous Therapeutics, Inc. - Non-Vaccine, Pan-Genus Prophylactics to Prevent COVID-19 and any Future Beta-Coronavirus Pandemic
00:47:38 – 00:53:56 Watch: Abimmune Biopharma Inc. - Respiviridin: A Universal Prophylactic & Therapeutic Candidate against Covid-19 and other Respiratory Viruses
LIGHTNING TALKS - SESSION 2: DEVICES/DIAGNOSTICS
00:00:00 – 00:05:49 Watch: Biomed Industries, Inc. - What does Covid-19 Virus do to the Brain?
00:05:50 – 00:11:42 Watch: Advanced Innovative Partners/Bio-Nucleonics - Treatment of COVID-19 Virus
00:11:43 – 00:17:28 Watch: HDT Bio Corp. - Development of RNA-based PAMP Plus LION as a Novel Antiviral Therapy to Limit COVID-19
00:17:29 – 00:23:18 Watch: KAER Biotherapeutics Corporation - Therapeutic Surfactant and Biologics Aerosols for the Treatment of Hypoxemia and Respiratory Distress
00:23:19 – 00:28:48 Watch: Zim Biosciences Inc. - A Technology for the Amelioration of Thermal and/or Chemical Insults to Lung Tissue
00:28:49 – 00:33:50 Watch: VitriVax - Thermostable, Single-Shot Vaccine Formulation Platform
00:33:51 – 00:39:43 Watch: FluGen Inc. - M2SR Seroconversion Against H3N2 Proximate & Distant Drift
00:39:44 – 00:45:12 Watch: Virica Biotech Inc. - Viral Sensitizers: Accelerating Vaccine Production and Pandemic Response
00:45:13 – 00:51:05 Watch: Codex DNA - Establishing a Global Network of Vaccine Printers
00:51:06 – 00:57:03 Watch: Persephone Biosciences - Arming the Immune System Using Gut Microbiome Therapeutics to Prevent and Fight SARS-CoV-2

Presented By